Quick Summary

Danshen (Salvia miltiorrhiza) is a traditional Chinese medicinal herb extensively studied for its potential effects in cardiovascular, metabolic, neurological, renal, and inflammatory conditions. Clinical and preclinical evidence suggests Danshen may help improve cardiac and renal function, modulate inflammatory and oxidative stress markers, and enhance metabolic profiles. However, the quality of many clinical studies varies, and large-scale, high-quality trials are needed to more definitively confirm its efficacy and safety.

What Is It?

Danshen, also known by its botanical name Salvia miltiorrhiza, is a perennial herb native to China and widely used in traditional Chinese medicine (TCM). Its dried root is the part most commonly used for medicinal purposes. Danshen contains various bioactive compounds that are believed to contribute to its medicinal properties.

Traditional Uses

Danshen has been traditionally used in Chinese medicine to support cardiovascular health, improve blood circulation, alleviate chest pain, treat menstrual disorders, and promote detoxification. It has also been applied for symptoms related to inflammation, liver disorders, and neurological conditions.

Active Compounds

Key active compounds in Danshen include tanshinones (lipophilic diterpenoids), salvianolic acids (water-soluble phenolic acids), and other constituents such as salvianolic acid B and danshensu. These compounds are studied for their antioxidant, anti-inflammatory, and vascular effects.

Potential Benefits with Evidence Levels

  • Cardiovascular Health (Moderate Evidence): Meta-analyses and randomized controlled trials (RCTs) indicate Danshen preparations may improve cardiac function, including left ventricular ejection fraction, reduce angina symptoms, and potentially prevent cardiotoxicity from certain chemotherapy drugs. Mechanistic studies suggest anti-inflammatory, anti-fibrotic, and endothelial protective effects.
  • Diabetic Nephropathy and Kidney Function (Moderate Evidence): Systematic reviews report Danshen and related injections might improve renal markers such as serum creatinine and albuminuria, and reduce inflammatory cytokines in diabetic kidney disease with acceptable safety.
  • Stroke and Neurological Recovery (Low to Moderate Evidence): Animal studies and some clinical data suggest Danshen extracts may aid neurological and motor function recovery post-ischemic stroke and spinal cord injury, though clinical evidence quality is limited.
  • Dyslipidemia (Moderate Evidence): Danshen combined with statins may improve lipid profiles by lowering total cholesterol, LDL cholesterol, and triglycerides while raising HDL cholesterol, possibly via PI3K/Akt pathway modulation.
  • Diabetes and Metabolic Disease (Low to Moderate Evidence): Traditional formulations containing Danshen show preliminary benefits in glycemic control, insulin resistance, and metabolic parameters in type 2 diabetes and metabolic-associated steatotic liver disease.
  • Inflammatory Conditions and Immunomodulation (Low to Moderate Evidence): Danshen preparations may reduce inflammatory markers like TNF-α, IL-6, and hs-CRP, and improve endothelial function in conditions such as unstable angina and rheumatoid arthritis, with generally low short-term adverse effects.
  • Other Potential Uses (Preclinical or Insufficient Evidence): Early studies and computational analyses suggest potential roles in viral myocarditis, post-stroke cognition, and tumor immunotherapy support. However, clinical evidence remains scarce.

Side Effects

Danshen is generally well tolerated. Mild and infrequent adverse effects have been reported in some injection formulations, but no significant increase in serious adverse events has been identified compared to controls. Safety data from long-term, high-quality studies remain limited.

Drug Interactions

There is limited robust evidence regarding herb-drug interactions. However, caution is advised when using Danshen concurrently with anticoagulants, antiplatelet agents, or other cardiovascular drugs due to its potential effects on blood coagulation and cardiovascular parameters.

Who Should Avoid It?

  • Individuals on anticoagulant or antiplatelet therapy should use Danshen cautiously until more safety data are available.
  • Due to insufficient safety data, use during pregnancy and breastfeeding is not recommended unless the potential benefits outweigh risks and under professional medical supervision.
  • No specific contraindications have been identified in available clinical evidence.

Evidence Limitations

  • Many systematic reviews and meta-analyses report low to moderate methodological quality, with risks of bias including lack of blinding and small sample sizes.
  • Variability in Danshen formulations, dosages, and study designs limits applicability and generalizability of findings.
  • Much of the evidence for some indications is based on animal and in vitro studies with limited clinical translation.
  • Long-term safety and pharmacokinetic data are scarce.
  • There is a need for large, high-quality, multicenter randomized controlled trials with sufficient follow-up duration.

References

Last Reviewed

June 2024

Disclaimer: This page is for informational purposes only and does not constitute medical advice. Danshen should not replace conventional medical treatment. Always consult a qualified healthcare professional before starting any herbal therapy, especially if you have existing health conditions or take other medications.